Illinois Municipal Retirement Fund Makes New Investment in Enovis Corporation (NYSE:ENOV)

Illinois Municipal Retirement Fund purchased a new stake in shares of Enovis Corporation (NYSE:ENOV - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,786 shares of the company's stock, valued at approximately $1,138,000. Illinois Municipal Retirement Fund owned 0.05% of Enovis as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in Enovis in the fourth quarter worth $29,000. Quadrant Capital Group LLC grew its stake in shares of Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares during the period. Farther Finance Advisors LLC increased its holdings in Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after acquiring an additional 536 shares during the last quarter. Quarry LP raised its stake in Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 749 shares during the period. Finally, GAMMA Investing LLC raised its stake in Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after acquiring an additional 692 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. JMP Securities cut their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Needham & Company LLC dropped their price target on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Price Performance

NYSE ENOV traded up $0.19 during trading hours on Thursday, hitting $33.65. The company had a trading volume of 775,291 shares, compared to its average volume of 889,392. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.32 and a current ratio of 2.55. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -2.41 and a beta of 1.70. Enovis Corporation has a 52 week low of $28.83 and a 52 week high of $49.83. The firm has a 50 day simple moving average of $33.02 and a 200 day simple moving average of $38.06.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The company's revenue for the quarter was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.50 earnings per share. Equities research analysts expect that Enovis Corporation will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.